268 related articles for article (PubMed ID: 19386496)
1. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Kamath VP; Xue J; Juarez-Brambila JJ
Bioorg Med Chem Lett; 2009 May; 19(10):2627-9. PubMed ID: 19386496
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Kamath VP; Xue J; Juarez-Brambila JJ; Morris CB; Ganorkar R; Morris PE
Bioorg Med Chem Lett; 2009 May; 19(10):2624-6. PubMed ID: 19386498
[TBL] [Abstract][Full Text] [Related]
3. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
4. Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
Evans GB; Furneaux RH; Lewandowicz A; Schramm VL; Tyler PC
J Med Chem; 2003 Jul; 46(15):3412-23. PubMed ID: 12852771
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylase via the Mannich reaction.
Evans GB; Furneaux RH; Tyler PC; Schramm VL
Org Lett; 2003 Oct; 5(20):3639-40. PubMed ID: 14507192
[TBL] [Abstract][Full Text] [Related]
6. Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases.
Clinch K; Evans GB; Fleet GW; Furneaux RH; Johnson SW; Lenz DH; Mee SP; Rands PR; Schramm VL; Taylor Ringia EA; Tyler PC
Org Biomol Chem; 2006 Mar; 4(6):1131-9. PubMed ID: 16525558
[TBL] [Abstract][Full Text] [Related]
7. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
Miles RW; Tyler PC; Furneaux RH; Bagdassarian CK; Schramm VL
Biochemistry; 1998 Jun; 37(24):8615-21. PubMed ID: 9628722
[TBL] [Abstract][Full Text] [Related]
8. [Tight binding transition state analogues of purine nucleoside phosphorylase--meaning, design and properties].
Lewandowicz A
Postepy Biochem; 2004; 50(3):218-27. PubMed ID: 15822751
[No Abstract] [Full Text] [Related]
9. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
10. 8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
Evans GB; Furneaux RH; Gainsford GJ; Hanson JC; Kicska GA; Sauve AA; Schramm VL; Tyler PC
J Med Chem; 2003 Jan; 46(1):155-60. PubMed ID: 12502369
[TBL] [Abstract][Full Text] [Related]
11. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
12. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Gandhi V; Kilpatrick JM; Plunkett W; Ayres M; Harman L; Du M; Bantia S; Davisson J; Wierda WG; Faderl S; Kantarjian H; Thomas D
Blood; 2005 Dec; 106(13):4253-60. PubMed ID: 16131572
[TBL] [Abstract][Full Text] [Related]
13. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040.
Kezar HS; Kilpatrick JM; Phillips D; Kellogg D; Zhang J; Morris PE
Nucleosides Nucleotides Nucleic Acids; 2005; 24(10-12):1817-30. PubMed ID: 16438050
[TBL] [Abstract][Full Text] [Related]
15. New catalytic mechanism for human purine nucleoside phosphorylase.
Canduri F; Fadel V; Basso LA; Palma MS; Santos DS; de Azevedo WF
Biochem Biophys Res Commun; 2005 Feb; 327(3):646-9. PubMed ID: 15649395
[TBL] [Abstract][Full Text] [Related]
16. Current developments in the synthesis and biological activity of aza-C-nucleosides: immucillins and related compounds.
Merino P; Tejero T; Delso I
Curr Med Chem; 2008; 15(10):954-67. PubMed ID: 18393853
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
Gandhi V; Balakrishnan K
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
[TBL] [Abstract][Full Text] [Related]
18. The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
Deves C; de Assunção TM; Ducati RG; Campos MM; Basso LA; Santos DS; Batista EL
Bone; 2013 Jan; 52(1):167-75. PubMed ID: 23026564
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase.
Kamath VP; Juarez-Brambila JJ; Morris PE
Drug Test Anal; 2009 Mar; 1(3):125-7. PubMed ID: 20355185
[TBL] [Abstract][Full Text] [Related]
20. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
Furman RR; Hoelzer D
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
